All In Biotech

Drug Trial Radar · NCT06974084

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Dec 1, 2026

Study completion May 2027

Sponsor

Lead sponsor
HealthBio, Inc.Industry
Sponsor type
Industry
Collaborators
Lindus Health, Inc.
First posted
May 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID. The main goals of the clinical study are to determine if this combination drug therapy can improve neurocognitive and physical functions in Long Covid patients, such as fatigue severity, heart rate, blood pressure, digestion, breathing, dizziness, and cognitive function. A secondary goal is to determine if biomarker levels, measured by a diagnostic test, can improve during treatment. To qualify for the trial, a subject must be an adult ≥ 18 and ≤ 65 years of age and meets the WHO-defined post-COVID-19 condition and has one or more new-onset Long Covid symptom that persist ≥ 3 months after the diagnosis of acute COVID-19 infection. A total of 252 participants will take either two daily doses of two existing medications (Maraviroc and Atorvastatin together as separate tablets) or a placebo (pills with no active ingredient) for 16 weeks. Although these medications are not yet approved for Long Covid, they are FDA-approved for use in treating other health conditions.

Conditions

  • Long COVID

Interventions

  • Maraviroc (MVC)Drug

    Maraviroc, 300mg per tablet. Atorvastatin, 10mg per tablet

  • Atorvastatin, 10mg, 20mg, 40mgDrug

    Atorvastatin, 10mg will be given twice daily oral along with Maraviroc, 300-mg

  • Placebo, MaravirocDrug

    Placebo of Maraviroc, 300mg

  • Placebo, AtorvastatinDrug

    Placebo of Atorvastin, 10mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FatigueTime frame: PROMIS Fatigue scores will be taken during screening (0-28 days before the first baseline) and at the EOT visit, week 12.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.